Embecta (EMBC) Competitors $18.96 -0.17 (-0.89%) As of 01/24/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EMBC vs. PRCT, NVST, IRTC, NVCR, LIVN, ENOV, WRBY, TNDM, LMAT, and CNMDShould you be buying Embecta stock or one of its competitors? The main competitors of Embecta include PROCEPT BioRobotics (PRCT), Envista (NVST), iRhythm Technologies (IRTC), NovoCure (NVCR), LivaNova (LIVN), Enovis (ENOV), Warby Parker (WRBY), Tandem Diabetes Care (TNDM), LeMaitre Vascular (LMAT), and CONMED (CNMD). These companies are all part of the "medical equipment" industry. Embecta vs. PROCEPT BioRobotics Envista iRhythm Technologies NovoCure LivaNova Enovis Warby Parker Tandem Diabetes Care LeMaitre Vascular CONMED PROCEPT BioRobotics (NASDAQ:PRCT) and Embecta (NASDAQ:EMBC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations. Which has higher valuation and earnings, PRCT or EMBC? Embecta has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPROCEPT BioRobotics$136.19M28.15-$105.90M-$1.95-37.67Embecta$1.12B0.98$78.30M$1.3514.04 Do analysts rate PRCT or EMBC? PROCEPT BioRobotics currently has a consensus target price of $97.86, suggesting a potential upside of 33.21%. Embecta has a consensus target price of $23.00, suggesting a potential upside of 21.31%. Given PROCEPT BioRobotics' stronger consensus rating and higher probable upside, equities analysts clearly believe PROCEPT BioRobotics is more favorable than Embecta.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PROCEPT BioRobotics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Embecta 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is PRCT or EMBC more profitable? Embecta has a net margin of 6.97% compared to PROCEPT BioRobotics' net margin of -50.07%. Embecta's return on equity of -18.54% beat PROCEPT BioRobotics' return on equity.Company Net Margins Return on Equity Return on Assets PROCEPT BioRobotics-50.07% -38.57% -26.06% Embecta 6.97%-18.54%11.43% Does the media favor PRCT or EMBC? In the previous week, PROCEPT BioRobotics had 5 more articles in the media than Embecta. MarketBeat recorded 6 mentions for PROCEPT BioRobotics and 1 mentions for Embecta. PROCEPT BioRobotics' average media sentiment score of 1.14 beat Embecta's score of 0.77 indicating that PROCEPT BioRobotics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in PRCT or EMBC? PROCEPT BioRobotics received 37 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 67.86% of users gave PROCEPT BioRobotics an outperform vote while only 6.25% of users gave Embecta an outperform vote. CompanyUnderperformOutperformPROCEPT BioRoboticsOutperform Votes3867.86% Underperform Votes1832.14% EmbectaOutperform Votes16.25%Underperform Votes1593.75% Do insiders and institutionals hold more shares of PRCT or EMBC? 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 0.4% of Embecta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, PRCT or EMBC? PROCEPT BioRobotics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Embecta has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. SummaryPROCEPT BioRobotics beats Embecta on 9 of the 17 factors compared between the two stocks. Get Embecta News Delivered to You Automatically Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EMBC vs. The Competition Export to ExcelMetricEmbectaSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.09B$4.92B$5.45B$9.27BDividend Yield3.20%52.56%5.37%3.98%P/E Ratio14.0415.3462.6314.11Price / Sales0.9857.051,231.2280.00Price / Cash5.6252.0644.3737.67Price / Book-1.488.175.094.75Net Income$78.30M$13.87M$117.85M$224.45M7 Day Performance1.50%3.96%3.15%1.44%1 Month Performance-6.51%11.23%4.03%3.27%1 Year Performance12.06%36.77%28.50%22.21% Embecta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EMBCEmbecta3.6632 of 5 stars$18.96-0.9%$23.00+21.3%+12.4%$1.09B$1.12B14.042,100News CoveragePRCTPROCEPT BioRobotics2.9403 of 5 stars$76.02-3.6%$97.86+28.7%+62.0%$3.97B$136.19M-38.98430High Trading VolumeNVSTEnvista3.5868 of 5 stars$19.83+3.3%$20.21+1.9%-10.2%$3.41B$2.57B-2.5512,800Analyst ForecastNews CoverageIRTCiRhythm Technologies1.0229 of 5 stars$108.33+1.3%$108.45+0.1%-5.6%$3.39B$492.68M-22.292,000NVCRNovoCure3.1233 of 5 stars$26.17+0.6%$32.67+24.8%+88.0%$2.83B$509.34M-18.691,453LIVNLivaNova3.6053 of 5 stars$48.30+0.7%$69.17+43.2%-1.6%$2.62B$1.15B115.002,900Analyst DowngradeENOVEnovis3.0849 of 5 stars$46.68+2.7%$67.00+43.5%-18.6%$2.61B$1.71B-21.326,550WRBYWarby Parker2.3335 of 5 stars$24.57-6.3%$20.92-14.9%+99.1%$2.50B$669.77M-90.983,491Analyst ForecastNews CoverageTNDMTandem Diabetes Care4.4406 of 5 stars$35.15-6.3%$53.81+53.1%+57.7%$2.31B$747.72M-18.212,400Positive NewsLMATLeMaitre Vascular3.1142 of 5 stars$99.06+0.8%$94.57-4.5%+68.6%$2.23B$193.48M54.13490Analyst RevisionNews CoveragePositive NewsCNMDCONMED4.773 of 5 stars$67.75+1.3%$79.80+17.8%-24.5%$2.09B$1.24B16.094,000Positive News Related Companies and Tools Related Companies PRCT Alternatives NVST Alternatives IRTC Alternatives NVCR Alternatives LIVN Alternatives ENOV Alternatives WRBY Alternatives TNDM Alternatives LMAT Alternatives CNMD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EMBC) was last updated on 1/25/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
